| Q38043434 | 'Innovation' in health care coverage decisions: all talk and no substance? |
| Q62000244 | A Stated Preference Binary Choice Experiment to Explore NICE Decision Making |
| Q81657271 | A response to Birch and Gafni--some reasons to be cheerful about NICE |
| Q48572824 | Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal |
| Q38257384 | Bridging the gap: exploring the barriers to using economic evidence in healthcare decision making and strategies for improving uptake |
| Q37207605 | Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective |
| Q82623181 | Darzi on NICE: the case for clinician engagement in HTA |
| Q34790212 | Decision maker perceptions of resource allocation processes in Canadian health care organizations: a national survey |
| Q43874762 | Decision making by NICE: examining the influences of evidence, process and context |
| Q34362510 | Decision-making in healthcare: a practical application of partial least square path modelling to coverage of newborn screening programmes |
| Q40537454 | Economic Evaluation in Ethiopian Healthcare Sector Decision Making: Perception, Practice and Barriers |
| Q36635514 | Economic evaluation and decision making in the UK. |
| Q51826313 | Effectiveness in political--administrative decision-making in specialized healthcare. |
| Q35898829 | Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa |
| Q37453295 | Fixing the game: are between-silo differences in funding arrangements handicapping some interventions and giving others a head-start? |
| Q46035621 | Has the time come for cost-effectiveness analysis in US health care? |
| Q81049497 | Increasing decision-makers' access to economic evaluations: alternative methods of communicating the information |
| Q51200231 | Link between process and appraisal in coverage decisions: an analysis with structural equation modeling. |
| Q47123934 | Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR). |
| Q50636366 | Methodological considerations in service use assessment for children and youth with mental health conditions; issues for economic evaluation. |
| Q34719713 | NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? |
| Q91996928 | One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit |
| Q33655826 | Perspectives on econometric modelling to inform policy: a UK qualitative case study of minimum unit pricing of alcohol |
| Q43620093 | Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making. |
| Q57896209 | Qualitative methodologies in health-care priority setting research |
| Q46517834 | Requisite models for strategic commissioning: the example of type 1 diabetes. |
| Q34433370 | STAR--people-powered prioritization: a 21st-century solution to allocation headaches |
| Q37945042 | Systematic review and empirical comparison of contemporaneous EQ-5D and SF-6D group mean scores |
| Q40735681 | The Role of Decision Models in Health Care Policy: A Case Study. |
| Q37722654 | The Role of Qualitative Research Methods in Discrete Choice Experiments |
| Q48628756 | The changing role of economic evaluation in valuing medical technologies |
| Q33834292 | The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation? |
| Q130317970 | Untangling the Complexity of Funding Recommendations: A Comparative Analysis of Health Technology Assessment Outcomes in Four European Countries |
| Q41984323 | Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden |
| Q57412529 | Using CART to Identify Thresholds and Hierarchies in the Determinants of Funding Decisions |